Workflow
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference
KYMRKymera Therapeutics(KYMR) GlobeNewswire· Globenewswire·2025-05-19 16:15

Core Insights - Kymera Therapeutics announced promising preclinical data for KT-621, an oral STAT6 degrader, showing comparable or superior efficacy to dupilumab in chronic asthma models [1][3] - The company has completed a Phase 1 trial for KT-621 and plans to report data in June 2025, with ongoing trials for atopic dermatitis and upcoming Phase 2b trials for asthma and atopic dermatitis [4][1] Group 1: KT-621 Development - KT-621 is the first STAT6 targeted medicine to enter clinical development, demonstrating potential as a once-daily oral treatment for asthma and other Th2 allergic diseases [1][6] - Preclinical data indicate that KT-621 can prevent disease progression and reverse established disease in asthma models, outperforming dupilumab in certain metrics [3][1] - The company plans to initiate two parallel Phase 2b trials in atopic dermatitis and asthma in late 2025 and early 2026, respectively [4][1] Group 2: Clinical Trials and Data - The Phase 1 healthy volunteer trial for KT-621 has been completed, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics [4][1] - Data from the ongoing KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis patients is expected in the fourth quarter of 2025 [4][1] - A webcast is scheduled for June 2025 to disclose comprehensive data from the Phase 1 trials, including safety and biomarker results [4][1] Group 3: Company Vision and Market Potential - Kymera Therapeutics aims to expand patient access to oral systemic therapies for immuno-inflammatory diseases, addressing a significant unmet need in the market [3][6] - The company emphasizes the convenience of KT-621 as an oral medication, which could reach broader patient populations compared to injectable biologics [6][3] - KT-621 has the potential to transform treatment paradigms for over 130 million patients globally suffering from Th2 diseases [6][1]